Search
Ixazomib
go.drugbank.com/drugs/DB09570ApprovedInvestigationalIxazomib is a reversible proteasome inhibitor. Because it is a modified peptide boronic acid with one chiral center,[A264329] it is considered a boronate proteasome inhibitor. … [L51244] It was also investigated in other hematological malignancies as well as other conditions, such as systemic light chain (AL) amyloidosis, graft-versus-host disease, and lupus nephritis.
Categories: Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2B6 Substrates with a Narrow Therapeutic IndexProducts: NİNLARO 2.3 MG MG KAPSÜL, 3 ADET, NINLARO® 3.0 MGEszopiclone
go.drugbank.com/drugs/DB00402ApprovedInvestigationalEszopiclone, marketed by Sepracor under the brand-name Lunesta, is a nonbenzodiazepine hypnotic drug used to treat insomnia. … [A179638,L6850] Cyclopyrrolone drugs demonstrate high efficacy and low toxicity[A179827], offering a safer alternative to other drugs used for insomnia.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesProducts: ISOKLON® 3 MG, ZOMILAN 1 MGBosentan
go.drugbank.com/drugs/DB00559ApprovedInvestigationalBosentan is a dual endothelin receptor antagonist marketed under the trade name Tracleer by Actelion Pharmaceuticals.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C9 InducersProducts: N/A, BOSENTAN AL 125MG FTAValethamate
go.drugbank.com/drugs/DB13497InvestigationalMixtures: EPIDOSIN COMPOSITUM 10 MG AMPUL, 3 ADETProducts: EPIDOSIN 10 MG SUPPOZITUAR, 6 ADET, EPIDOSIN 8 MG/8 ML AMPUL, 5 ADETRiociguat
go.drugbank.com/drugs/DB08931ApprovedInvestigationalRiociguat is a soluble guanylate cyclase (sGC) agonist approved in the USA, Europe and several other regions for patients with group I PAH (pulmonary arterial hypertension) in WHO FC II or III; and for
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A1 SubstratesProducts: Adempas 2 mg film-coated tablet, PULLMOGUAT® 2 MG TABLETA RECUBIERTAChondroitin sulfate
go.drugbank.com/drugs/DB09301ApprovedInvestigationalNutraceuticalChondroitin sulfate is a glycosaminoglycan considered as a symptomatic slow-acting drug for osteoarthritis (SYSADOA). … [A7906] The SYSADOA status suggested a pain relief and increased joint mobility after a relative long regular administration, as well as a long-lasting effect after the end of the treatment.
Mixtures: FLEXSA PLUS (1500 MG/1200 MG), GLUCOSAMINA SULFATO 1500 MG + CONDROITINA SULFATO 1200 MGProducts: Cartexan 400 mg Hartkapseln, Condrosulf 400 mg - KapselnSilodosin
go.drugbank.com/drugs/DB06207ApprovedInvestigationalSilodosin is a selective antagonist of alpha(α)-1 adrenergic receptors that binds to the α<sub>1A</sub> subtype with the highest affinity. α1-adrenergic receptors regulate smooth muscle tone in the bladder … neck, prostate, and prostatic urethra: the α<sub>1A</sub> subtype accounts for approximately 75% of α1-adrenoceptors in the prostate.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesProducts: SILODOSIN AL 4 MG HKP, SILODOSIN AL 8 MG HKPLevamlodipine
go.drugbank.com/drugs/DB09237ApprovedInvestigationalLevamlodipine, also known as S-amlodipine, is a pharmacologically active enantiomer of [amlodipine], an antihypertensive medication. … [L10833] As a racemic mixture, amlodipine contains (R) and (S)-amlodipine isomers, but only (S)-amlodipine as the active moiety possesses therapeutic activity.
Mixtures: ALENCAL IRBE® 2.5/150 MG TABLETAS RECUBIERTAS, ALENCAL IRBE® 2.5/150 MG TABLETAS RECUBIERTASCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesRotigotine
go.drugbank.com/drugs/DB05271ApprovedInvestigationalIt is formulated as a once-daily transdermal patch which provides a slow and constant supply of the drug over the course of 24 hours. … Rotigotine has been authorized as a treatment for RLS since August 2008.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C19 InhibitorsProducts: NEUPRO® 6 MG/24 H, NEUPRO® 4 MG /24 HCariprazine
go.drugbank.com/drugs/DB06016ApprovedInvestigational[A247100] It works as a partial agonist at central dopamine D2, dopamine D3, and serotonin 5-HT<sub>1A</sub> receptors and as an antagonist at serotonin 5-HT<sub>2A</sub> receptors. … Cariprazine is an atypical antipsychotic agent and a piperazine derivative that was first developed in Hungary.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 InhibitorsProducts: SYMVENU 1.5 MG, SYMVENU 3.0 MG